ClassID:

20466

A61K31/559 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen

Recent Application in this class:
#1
20250000695
2025-01-02

INTRAOCULAR IMPLANT WITH HIGH LOADING OF A PROSTAMIDE

#2
20240358714
2024-10-31

PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT

#3
20240197753
2024-06-20

PHARMACEUTICAL COMPOSITION FOR IMPROVING CARDIAC FUNCTION

#4
20240148750
2024-05-09

PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT

#5
20240082263
2024-03-14

PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY COMPRISING MELATONIN AND PROSTAGLANDIN E2 FOR TREATING INTESTINAL EPITHELIAL INJURY AS AN ACTIVE INGREDIENT

#6
20220401455
2022-12-22

BIODEGRADABLE DRUG-POLYMER CONJUGATE

#7
20220354865
2022-11-10

PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT

#8
20220088000
2022-03-24

COMBINATION THERAPY

#9
20220023095
2022-01-27

Intraocular implant with high loading of a prostamide

#10
20210244722
2021-08-12

Compositions for treating glaucoma or reducing intraocular pressure

#11
20210236477
2021-08-05

Combination therapy

#12
20210186985
2021-06-24

METHODS FOR TREATING DISEASES ASSOCIATED WITH CILIOPATHIES

#13
20210085690
2021-03-25

Composition and method of using eicosanoyl-5-hydroxytryptamide for treating neurodegenerative disorders

#14
20210085689
2021-03-25

PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT

#15
20200375953
2020-12-03

Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists

#16
20200276179
2020-09-03

Combination Therapy

#17
20200171007
2020-06-04

Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists

#18
20200129498
2020-04-30

Combination therapy

#19
20190343810
2019-11-14

Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists

#20
20190290722
2019-09-26

TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY

#21
20190247365
2019-08-15

Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists

#22
20190175475
2019-06-13

COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS

#23
20180344724
2018-12-06

Combination therapy

#24
20180333405
2018-11-22

Combination therapy

#25
20180161342
2018-06-14

Prostamide-containing intraocular implant

#26
20180071308
2018-03-15

Methods for fat reduction

#27
20170348214
2017-12-07

COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS

#28
20170319554
2017-11-09

Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists

#29
20170281613
2017-10-05

Combination therapy

#30
20170209532
2017-07-27

Two part formulation system for ophthalmic delivery

#31
20170151261
2017-06-01

SKIN WOUND HEALING AND SCAR REDUCTION WITH PROSTAGLANDIN EP4 AGONIST COMBINATIONS

#32
20170087163
2017-03-30

SOLID FORMS OF AN ALPHA, OMEGA DI-SUBSTITUTED DIHYDROXY CYCLOPENTYL COMPOUND AND METHODS FOR THE PREPARATION AND USE THEREOF

#33
20170071953
2017-03-16

Microsphere Drug Delivery System for Sustained Intraocular Release

#34
20160346269
2016-12-01

Combination therapy

#35
20160339039
2016-11-24

Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

#36
20160317550
2016-11-03

Methods for fat reduction

#37
20160243105
2016-08-25

Combination therapy

#38
20160235666
2016-08-18

Two part formulation system for ophthalmic delivery

#39
20160220677
2016-08-04

STABLE AQUEOUS COMPOSITIONS OF PROSTGLANDIN AGONIST PRODRUGS AND METHODS FOR USE THEREOF

#40
20160199387
2016-07-14

Prostamide-containing intraocular implant

#41
20160108012
2016-04-21

Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension

#42
20160106651
2016-04-21

Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

#43
20160096817
2016-04-07

Treatment of inflammatory bowel disease

#44
20150165067
2015-06-18

Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment

#45
20150018400
2015-01-15

Treatment of inflammatory bowel disease

#46
20140308354
2014-10-16

SUSTAINED RELEASE BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION

#47
20140275161
2014-09-18

Combination therapy

#48
20140235681
2014-08-21

Combination therapy for glaucoma

#49
20140235665
2014-08-21

ANTI-CONSTIPATION COMPOSITION

#50
20140107124
2014-04-17

Prostamides for the treatment of glaucoma and related diseases

#51
20140024587
2014-01-23

Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

#52
20130029919
2013-01-31

TWO PART FORMULATION SYSTEM FOR OPTHALMIC DELIVERY

#53
20120237598
2012-09-20

Anti-constipation composition

#54
20120202773
2012-08-09

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT

#55
20120142684
2012-06-07

COMPOUNDS AND METHODS FOR SKIN REPAIR

#56
20120046332
2012-02-23

COMPOSITIONS AND METHODS FOR TREATING CORNEAL HAZE

#57
20120022152
2012-01-26

Anti-constipation composition

#58
20110294893
2011-12-01

NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS

#59
20110172435
2011-07-14

Geminal dialkyl prostanoids

#60
20110152797
2011-06-23

Prostaglandins and analogues as agents for lowering intraocular pressure

#61
20110152328
2011-06-23

Combination Therapy For Glaucoma

#62
20110136872
2011-06-09

STABLE AQUEOUS COMPOSITIONS OF PROSTGLANDIN AGONIST PRODRUGS AND METHODS FOR USE THEREOF

#63
20110062165
2011-03-17

Therapeutic substituted cyclopentanes

#64
20110015238
2011-01-20

Blood flow promoters for cauda equina tissues

#65
20100081631
2010-04-01

METHODS AND COMPOSITIONS FOR TREATING GASTROINTENSTIAL DISORDERS

#66
20100035868
2010-02-11

METHODS OF TREATMENT OF UTERINE PATHOLOGICAL CONDITIONS

#67
20100010222
2010-01-14

Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient

#68
20090286769
2009-11-19

Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

#69
20090227672
2009-09-10

Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

#70
20080286251
2008-11-20

Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins

#71
20080103184
2008-05-01

COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS

#72
20080039507
2008-02-14

Prostamides for the treatment of glaucoma and related diseases

#73
20080021021
2008-01-24

Preventive and/or remedy for lower urinary tract diseases containing EPagonist

#74
20070129327
2007-06-07

Blood flow promoters for cauda equina tissues

#75
20070099984
2007-05-03

Prostaglandins and analogues as agents for lowering intraocular pressure

#76
20050222232
2005-10-06

Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

#77
20050222195
2005-10-06

Anti-constipation composition

#78
20050222094
2005-10-06

Treatment of inflammatory bowel disease

#79
20050209194
2005-09-22

Combination therapy for glaucoma treatment

#80
20050164992
2005-07-28

Treatment of inflammatory bowel disease

#81
20050020686
2005-01-27

Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient